24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Stock
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
17:21
Former Mossad chief and real estate tycoons back controversial Israeli drone company
13:31
New Grok Imagine limits spark user fury: Continues glitch or policy shift?
08:51
Jensen Huang: Nvidia “100% in Israel” despite war
21:56
Israel’s war with Iran costs up to $550 million a day
More stories
Buzz
Most popular
Daily
Weekly
1
New Grok Imagine limits spark user fury: Continues glitch or policy shift?
2
Israeli startup Thermagix claims “the only economical solution for harvesting low-grade heat”
3
Oasis Security raises $120 million Series B to secure the rise of AI agents
4
Israel’s war with Iran costs up to $550 million a day
5
Former Mossad chief and real estate tycoons back controversial Israeli drone company
More news
Stock
6 stories about Stock
Emails in Mobileye Insider Trading Case Pinpoint Leak’s Source
18.12.17
|
Tomer Ganon and Ran Abramson
The documents show how defendants communicated information about the stock’s expected spike
Israeli Defendant Denies Mobileye Insider Trading Charges
08.12.17
|
Tomer Ganon and Ran Abramson
Amir Waldman, former vice president of Israel-based medical device company Syneron Medical, is being accused by the SEC of making over $4 million from insider trading in Mobileye securities
Allergan to Sell Teva Shares to J.P. Morgan
14.11.17
|
Dror Reich and Lilach Baumer
Allergan announced it pledged its 9.8% stake in Teva to J.P. Morgan as collateral, as part of a loan agreement. The company already agreed to sell a quarter of the stock in the first quarter of 2018
MediWound Loses Stock Purchase Agreement Case
14.11.17
|
Dror Reich
The burn and wound treatment company was ordered to follow through on previous agreement to buy shares of biotech company Polyheal
Allergan Planning Sale of its Teva Stock
01.11.17
|
Dror Reich and Lilach Baumer
For the third quarter of 2017, Allergan reported an operating loss of $4.02 billion, $1.3 billion of which is due to the depreciation of its Teva securities.
Teva Offloads Holdings in Australia’s Mesoblast
25.10.17
|
Dror Reich and Lilach Baumer
The stem-cell therapy company diluted Teva’s shares through a new offering in August
Previous Articles
